{"id":28238,"date":"2025-07-21T09:46:22","date_gmt":"2025-07-21T09:46:22","guid":{"rendered":"https:\/\/www.hotelsalepage.com\/feed\/cision-pr-newswire\/corestemchemon-expands-global-cro-reach-with-atg-lifetech-targeting-next-gen-preclinical-services\/"},"modified":"2025-07-21T09:46:22","modified_gmt":"2025-07-21T09:46:22","slug":"corestemchemon-expands-global-cro-reach-with-atg-lifetech-targeting-next-gen-preclinical-services-2","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=28238","title":{"rendered":"CorestemChemon Expands Global CRO Reach with ATG Lifetech, Targeting Next-Gen Preclinical Services"},"content":{"rendered":"<p><i>Strategic partnership to deliver transcriptomics-powered, organoid-based preclinical testing for high-impact drug discovery<\/i>\u00a0<\/p>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">SEOUL, South Korea<\/span>, July 21, 2025 \/PRNewswire\/ &#8212; CorestemChemon, a leading GLP-certified preclinical CRO based in <span class=\"xn-location\">South Korea<\/span>, has entered into a strategic partnership with ATG Lifetech, a biotechnology company specializing in transcriptome analytics and organoid-based modeling. This collaboration aims to deliver next-generation, precision-driven non-clinical solutions to pharmaceutical companies and biotech ventures across the U.S., <span class=\"xn-location\">Europe<\/span>, and <span class=\"xn-location\">Asia<\/span>.<\/span><\/p>\n<p>Through this partnership, the two companies will co-develop:<\/p>\n<ul type=\"disc\">\n<li>A transcriptome-based evaluation platform for predictive drug efficacy and safety profiling<\/li>\n<li>Disease-relevant organoid models for liver, heart, and the blood-brain barrier (BBB)<\/li>\n<li>A high-throughput transcriptomics analytics service for differentiating true vs. false positives in tumorigenicity studies<\/li>\n<li>Shared access to regulatory-aligned expertise for global clients targeting FDA\/EMA pathways<\/li>\n<\/ul>\n<p>&#8220;ATG Lifetech&#8217;s disruptive transcriptome and organoid platforms will significantly elevate the scientific fidelity of our preclinical services,&#8221; said a CorestemChemon spokesperson. &#8220;This alliance positions us to compete as a global CRO partner offering best-in-class biological relevance and regulatory readiness.&#8221;<\/p>\n<p>Organoid-based assays are increasingly recognized for their translational advantage, offering up to <b>5x greater predictive accuracy<\/b> in toxicity and efficacy screening compared to conventional 2D cell cultures, according to industry benchmarks. When integrated with whole-transcriptome analysis, these platforms enable earlier go\/no-go decisions in drug pipelines, helping clients de-risk clinical entry and reduce overall development timelines.<\/p>\n<p>&#8220;Investors should note that this partnership directly supports CorestemChemon&#8217;s strategic growth plan to expand high-margin, IP-driven CRO services globally. Revenue-generating service offerings are expected to begin rolling out by late 2025, with significant global demand already projected.&#8221;<\/p>\n<p>ATG Lifetech brings validated expertise from its international collaborations, including with ACROBiosystems (<span class=\"xn-location\">Switzerland<\/span>), and has been selected as a core developer in several South Korean government-backed biopharma initiatives.<\/p>\n<p>The two companies plan to showcase their joint research outputs at a major toxicology and preclinical science conference in Q4 2025. Global service launches will follow, focused on biotech and pharmaceutical customers in need of high-content, biologically faithful preclinical testing.<\/p>\n<p><i>CorestemChemon (KOSDAQ: 166480) is a full-service preclinical CRO with over two decades of experience in GLP-based toxicology, pharmacokinetics, and regulatory compliance. The company operates multiple AAALAC-certified facilities and partners with leading biopharmaceutical innovators across <span class=\"xn-location\">Asia<\/span>, the U.S., and <span class=\"xn-location\">Europe<\/span>.<\/i><\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<p><i>Strategic partnership to deliver transcriptomics-powered, organoid-based preclinical testing for high-impact drug discovery<\/i>\u00a0<\/p>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">SEOUL, South Korea<\/span>, July 21, 2025 \/PRNewswire\/ &#8212; CorestemChemon, a leading GLP-certified preclinical CRO based in <span class=\"xn-location\">South Korea<\/span>, has entered into a strategic partnership with ATG Lifetech, a biotechnology company specializing in transcriptome analytics and organoid-based modeling. This collaboration aims to deliver next-generation, precision-driven non-clinical solutions to pharmaceutical companies and biotech ventures across the U.S., <span class=\"xn-location\">Europe<\/span>, and <span class=\"xn-location\">Asia<\/span>.<\/span><\/p>\n<p>Through this partnership, the two companies will co-develop:<\/p>\n<ul type=\"disc\">\n<li>A transcriptome-based evaluation platform for predictive drug efficacy and safety profiling<\/li>\n<li>Disease-relevant organoid models for liver, heart, and the blood-brain barrier (BBB)<\/li>\n<li>A high-throughput transcriptomics analytics service for differentiating true vs. false positives in tumorigenicity studies<\/li>\n<li>Shared access to regulatory-aligned expertise for global clients targeting FDA\/EMA pathways<\/li>\n<\/ul>\n<p>&#8220;ATG Lifetech&#8217;s disruptive transcriptome and organoid platforms will significantly elevate the scientific fidelity of our preclinical services,&#8221; said a CorestemChemon spokesperson. &#8220;This alliance positions us to compete as a global CRO partner offering best-in-class biological relevance and regulatory readiness.&#8221;<\/p>\n<p>Organoid-based assays are increasingly recognized for their translational advantage, offering up to <b>5x greater predictive accuracy<\/b> in toxicity and efficacy screening compared to conventional 2D cell cultures, according to industry benchmarks. When integrated with whole-transcriptome analysis, these platforms enable earlier go\/no-go decisions in drug pipelines, helping clients de-risk clinical entry and reduce overall development timelines.<\/p>\n<p>&#8220;Investors should note that this partnership directly supports CorestemChemon&#8217;s strategic growth plan to expand high-margin, IP-driven CRO services globally. Revenue-generating service offerings are expected to begin rolling out by late 2025, with significant global demand already projected.&#8221;<\/p>\n<p>ATG Lifetech brings validated expertise from its international collaborations, including with ACROBiosystems (<span class=\"xn-location\">Switzerland<\/span>), and has been selected as a core developer in several South Korean government-backed biopharma initiatives.<\/p>\n<p>The two companies plan to showcase their joint research outputs at a major toxicology and preclinical science conference in Q4 2025. Global service launches will follow, focused on biotech and pharmaceutical customers in need of high-content, biologically faithful preclinical testing.<\/p>\n<p><i>CorestemChemon (KOSDAQ: 166480) is a full-service preclinical CRO with over two decades of experience in GLP-based toxicology, pharmacokinetics, and regulatory compliance. The company operates multiple AAALAC-certified facilities and partners with leading biopharmaceutical innovators across <span class=\"xn-location\">Asia<\/span>, the U.S., and <span class=\"xn-location\">Europe<\/span>.<\/i><\/p>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-28238","post","type-post","status-publish","format-standard","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/28238","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=28238"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/28238\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=28238"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=28238"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=28238"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}